Our recently published systematic review and meta-analysis of heart failure (HF) remote monitoring using implantable devices (Hajduczok et al. in HF Reviews 1–20, 1) has been updated to reflected new data from the GUIDE-HF trial (Lindenfeld et al. in Lancet 398(10304):991-1001, 2). Data from randomized controlled trials (RCTs) was assessed to determine the effectiveness of implantable remote monitoring on the improvement of outcomes in HF patients. With the inclusion of the data from 1000 patients followed for 12 months in GUIDE-HF, our conclusions remain unchanged: Compared to standard of care, remote monitoring using implantable devices did not reduce mortality, CV, or HF hospitalizations. However, right ventricular/pulmonary pressure monitoring may reduce HF hospitalizations.

我们最近发表的关于使用植入式设备进行心力衰竭 (HF) 远程监测的系统评价和荟萃分析（Hajduczok 等人在 HF 评论 1-20, 1）已更新，以反映来自 GUIDE-HF 试验的新数据（Lindenfeld 等人）等人在柳叶刀 398(10304):991-1001, 2)。评估来自随机对照试验 (RCT) 的数据，以确定植入式远程监测对 HF 患者预后改善的有效性。在 GUIDE-HF 中纳入了 1000 名患者随访 12 个月的数据，我们的结论保持不变：与护理标准相比，使用植入式设备进行远程监测并没有降低死亡率、CV 或 HF 住院率。然而，右心室/肺压监测可能会减少心衰住院。